Loomis Sayles & Co. L P Purchases 1,326,497 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Loomis Sayles & Co. L P lifted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) by 153.7% during the third quarter, HoldingsChannel reports. The firm owned 2,189,601 shares of the company’s stock after purchasing an additional 1,326,497 shares during the period. Loomis Sayles & Co. L P’s holdings in Myriad Genetics were worth $59,973,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Fisher Asset Management LLC grew its holdings in Myriad Genetics by 47.8% in the 3rd quarter. Fisher Asset Management LLC now owns 602,842 shares of the company’s stock valued at $16,512,000 after buying an additional 195,094 shares during the last quarter. Simplify Asset Management Inc. acquired a new stake in shares of Myriad Genetics in the third quarter worth $4,756,000. Earnest Partners LLC increased its position in Myriad Genetics by 3.5% during the second quarter. Earnest Partners LLC now owns 4,072,018 shares of the company’s stock worth $99,602,000 after acquiring an additional 138,960 shares during the period. Sei Investments Co. raised its stake in Myriad Genetics by 5.4% during the 2nd quarter. Sei Investments Co. now owns 2,417,192 shares of the company’s stock valued at $59,125,000 after purchasing an additional 124,007 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in Myriad Genetics in the 2nd quarter valued at $2,315,000. Institutional investors and hedge funds own 99.02% of the company’s stock.

Insider Buying and Selling at Myriad Genetics

In related news, Director Colleen F. Reitan sold 46,012 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the transaction, the director now owns 42,533 shares in the company, valued at $1,188,797.35. This represents a 51.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Paul J. Diaz sold 15,000 shares of the firm’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $22.93, for a total transaction of $343,950.00. Following the completion of the sale, the chief executive officer now owns 962,378 shares of the company’s stock, valued at $22,067,327.54. The trade was a 1.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,012 shares of company stock worth $1,900,485 over the last ninety days. Corporate insiders own 2.10% of the company’s stock.

Myriad Genetics Trading Up 2.4 %

Shares of NASDAQ:MYGN opened at $15.49 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The company’s fifty day moving average is $22.26 and its 200-day moving average is $24.49. Myriad Genetics, Inc. has a 52 week low of $14.72 and a 52 week high of $29.30.

Analysts Set New Price Targets

MYGN has been the topic of several research reports. JPMorgan Chase & Co. boosted their price objective on shares of Myriad Genetics from $17.00 to $20.00 and gave the stock an “underweight” rating in a report on Wednesday, August 7th. Wells Fargo & Company began coverage on Myriad Genetics in a report on Tuesday, August 27th. They issued an “overweight” rating and a $35.00 price target for the company. Scotiabank lifted their price objective on Myriad Genetics from $29.00 to $34.00 and gave the stock a “sector outperform” rating in a report on Tuesday, August 13th. Morgan Stanley lowered their price objective on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, November 18th. Finally, TD Cowen lifted their price target on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $27.36.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.